利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

427 条记录 (耗时 0.023 秒)

    A VAGINAL CONTRACEPTIVE COMPOSITION FOR REINFORCEMENT OF THE CERVICAL MUCUS BARRIER PROPERTIES
    1.
    发明公开
    A VAGINAL CONTRACEPTIVE COMPOSITION FOR REINFORCEMENT OF THE CERVICAL MUCUS BARRIER PROPERTIES 审中-公开

    公开(公告)号：US20240180956A1

    公开(公告)日：2024-06-06

    申请号：US18283757

    申请日：2022-04-07

    申请人： CIRQLE BIOMEDICAL CONTRACEPTION APS

    发明人： Thomas CROUZIER ,  Ulrike SCHIMPF

    IPC分类号： A61K31/722 ,  A61K9/00 ,  A61K9/06 ,  A61K47/34 ,  A61K47/38 ,  A61P15/18

    CPC分类号： A61K31/722 ,  A61K9/0034 ,  A61K9/06 ,  A61K47/34 ,  A61K47/38 ,  A61P15/18

    摘要： The disclosure relates to a vaginal contraceptive composition comprising one or more active ingredients and at least one formulation compound selected from a physiological acceptable gelling agent or a physiological acceptable carrier, wherein at least one of the one or more active ingredients is a mucoadhesive polymer, wherein said mucoadhesive polymer has a molecular weight between 90,000 Da and 350,000 Da, wherein said mucoadhesive polymer consists of a plurality of monomer units linked to each other via ether bonds, ester bonds, amide bonds, or combinations hereof, wherein said monomer units are selected from C6 sugars, amino-functionalised C6 sugars, amino acids, or combinations hereof, and wherein at least 50% of the monomer units comprise at least one amino group. The disclosure further relates to a use of a vaginal contraceptive composition, a vaginal contraceptive composition for use in therapy, a vaginal contraceptive composition for use as a contraceptive or contraceptive agent and a vaginal contraceptive composition for use in birth control or birth control therapy.

    NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING
    4.
    发明申请
    NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING 有权

    公开(公告)号：US20220387336A1

    公开(公告)日：2022-12-08

    申请号：US17835739

    申请日：2022-06-08

    申请人： University of Georgia Research Foundation, Inc.

    发明人： Sheba M. J. MohanKumar ,  Puliyur S. MohanKumar ,  Yen-Jun Chuang

    IPC分类号： A61K9/51 ,  A61K38/16 ,  A61P15/18 ,  A61P15/16

    摘要： Nanoparticles and formulations for non-surgical sterilization are disclosed herein. The nanoparticles for non-surgical sterilization contains a cage, such as a zeolitic imidazolate framework (“ZIF”), a surface modifying agent, a targeting ligand, and an active agent. The surface modifying agent is attached to the outer surface of the cage and the targeting ligand is exposed to the surrounding environment. The active agent is encapsulated in the cage. The targeting ligand binds to a reproductive hormone or a receptor of a reproductive hormone. The active agents can be a ribosome inactivating protein, an apoptosis inducer, a hormone, a receptor ligand, or a nucleic acid, or a combination thereof, that inactivates the ovaries or testes. Uses for the nanoparticles and formulations incorporating the nanoparticles for sterilizing a subject in need thereof are also disclosed.

    Orodispersible dosage unit containing an estetrol component
    5.
    发明授权
    Orodispersible dosage unit containing an estetrol component 有权

    公开(公告)号：US11147771B2

    公开(公告)日：2021-10-19

    申请号：US15737227

    申请日：2016-06-17

    申请人： ESTETRA SPRL

    发明人： Séverine Francine Isabelle Jaspart ,  Johannes Jan Platteeuw ,  Denny Johan Marijn Van Den Heuvel

    IPC分类号： A61K9/20 ,  A61K9/00 ,  A61K31/565 ,  A61K9/16 ,  A61P5/00 ,  A61P15/18

    摘要： The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 μg of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 μm to 50 μm. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.

    METHODS USING COMBINED ORAL CONTRACEPTIVE COMPOSITIONS WITH REDUCED CARDIOVASCULAR EFFECTS
    10.
    发明申请
    METHODS USING COMBINED ORAL CONTRACEPTIVE COMPOSITIONS WITH REDUCED CARDIOVASCULAR EFFECTS 审中-公开

    公开(公告)号：US20200046729A1

    公开(公告)日：2020-02-13

    申请号：US16573611

    申请日：2019-09-17

    申请人： ESTETRA SPRL

    发明人： Maud JOST ,  Glwadys RAUSIN

    IPC分类号： A61K31/565 ,  A61K31/585 ,  A61P15/18

    摘要： Described are combined oral contraceptive compositions with reduced cardiovascular effects and methods using them. In some embodiments, the methods relate to contraceptive methods or methods for treating dysmenorrhea with reduced cardiovascular effects, such as reduced venous thromboembolism (VTE) risk. The methods comprise administering to a female subject an effective amount of an estetrol component and a progestogenic component. The methods enjoy a favourable profile for thromboembolism compared to currently available methods which employs contraceptives from the so-called second, third or fourth generation.